Prevalence of *Anaplasma phagocytophilum* infection in feral cats in Massachusetts

Erin R Galemore, Mary A Labato and Elizabeth O’Neil

Abstract

**Objectives** The primary objective of this study was to determine the prevalence of *Anaplasma phagocytophilum* infection and exposure in adult feral cats in Massachusetts, an endemic area for *A phagocytophilum* and its tick vector *Ixodes scapularis*. The secondary objective was to determine if there were correlations between *A phagocytophilum* infection and the presence of anemia and thrombocytopenia.

**Methods** Blood samples were collected between June and December 2015 from 175 apparently healthy adult feral cats that were presented to trap and release spay/neuter centers in Massachusetts. Complete blood count, blood smear evaluation, SNAP 4Dx Plus test (IDEXX) and *A phagocytophilum* PCR were performed on all samples to document acute infection (PCR-positive and/or inclusions observed on blood smear) and exposure to *A phagocytophilum* (SNAP 4Dx Plus-positive for *A phagocytophilum* antibodies).

**Results** The prevalence of exposure to *A phagocytophilum* in feral cats in Massachusetts was 9.7%, whereas the prevalence of acute infection was 6.9%. All blood smears were negative for *Anaplasma* species inclusions; therefore, acute infection was defined as testing positive on PCR analysis. No statistically significant correlations were identified for cats that were positive for *A phagocytophilum* on PCR analysis or SNAP 4Dx Plus test and the presence of anemia or thrombocytopenia.

**Conclusions and relevance** The prevalence of *A phagocytophilum* exposure in feral cats approaches 10% and is higher than the previously reported national average prevalence of 4.3% in the USA. *A phagocytophilum* infection may be an emerging infectious disease in cats. Further research is needed to determine the prevalence of clinical illness associated with *A phagocytophilum* infection in cats living in endemic areas.

Accepted: 16 November 2017
Clinical signs reported included fever, pale mucous membranes, inappetence, lethargy, lameness, swollen and painful joints, and epistaxis. Hematologic evaluation showed anemia and thrombocytopenia in all cats. A case series of 16 cats from the northeastern USA with acute *A. phagocytophilum* infection was published in 2016. All cats in this study tested positive for *A. phagocytophilum* via PCR analysis with 3/16 cats also having morulae present within neutrophils. The most common clinical signs found were lethargy, fever and anorexia. These studies demonstrate that *A. phagocytophilum* is a causative agent of clinical disease in feline patients.

The prevalence of *Anaplasma* species infection in humans has grown tremendously in recent years. *A. phagocytophilum* infection became a reportable human infectious disease in 1999. The Centers for Disease Control report that the number of human cases in the USA more than doubled from 2007 to 2010. Also, a recent report on the prevalence of tick-borne diseases in dogs noted an increase in prevalence of *Anaplasma* species infection in the northeastern USA as compared with previous reports. In 2015, the year the current study was performed, the Companion Animal Parasite Council reported an 11.4% seroprevalence of *Anaplasma* species infection in dogs in Massachusetts. A study performed in 2007 by Billeter et al looked at the average prevalence of *Anaplasma* species infection in cats in the USA. Positive antibody titers were found in 4.3% of the cats and all cats were PCR-negative for *Anaplasma* species. Given the marked increase in human and canine cases of anaplasmosis in recent years, it is possible that the prevalence of feline anaplasmosis has also increased significantly; however, there are no previously published data available on the prevalence of feline anaplasmosis in the state of Massachusetts.

The primary objective of our study was to determine the prevalence of acute *A. phagocytophilum* infection and *A. phagocytophilum* exposure in feral cats living in Massachusetts, an area that has one of the highest incidences of *Anaplasma* species infection in humans and dogs. A secondary objective was to evaluate abnormalities in complete blood count (CBC) analyses to determine if there were correlations between *A. phagocytophilum* infection, exposure, and the presence of anemia and thrombocytopenia.

**Materials and methods**

The study population was comprised of adult feral cats presenting to two trap and release spay/neuter clinics in Massachusetts: the Lerner Clinic at Tufts Cummings School of Veterinary Medicine in North Grafton, MA, and Dakin Humane Society’s Spay/Neuter Clinic in Springfield, MA. All cats were trapped in the state of Massachusetts. Adult age was assessed based on the presence of adult dentition. All samples were collected while the cats were under anesthesia for routine castration or ovariohysterectomy. This study was approved by and conducted in accordance with the Institutional Animal Care and Use Committee at Tufts University.

Blood samples were collected from June to December 2015 and placed in sodium EDTA and serum separator tubes. After allowing time to clot, serum separator tubes were centrifuged for 10 mins to separate serum. Blood samples were stored on ice during transport from clinic to laboratory. CBC and blood smear preparation were performed on sodium EDTA whole-blood samples within 24 h of sample collection. CBC analyses were performed by IDEXX Laboratories and cats were considered to have anemia or thrombocytopenia when the values were below the laboratory reference interval. To document acute infection, blood smears were evaluated for the presence of morulae within neutrophils and whole-blood samples were submitted for PCR analysis. Blood smears were submitted to the clinical pathology laboratory at Tufts Cummings School of Veterinary Medicine for pathologist review. For consistency, a single clinical pathologist evaluated all blood smears (EO’N). Sodium EDTA whole-blood samples were submitted for *A. phagocytophilum* PCR analysis to IDEXX Laboratories. To document previous *Anaplasma* species exposure, serum samples were evaluated for *A. phagocytophilum* antibodies using a SNAP 4Dx Plus test (IDEXX) according to manufacturers’ guidelines. The *Anaplasma* portion of the SNAP 4Dx Plus test is not species-specific (unpublished data, personal communication with IDEXX Medical Affairs Manager, September 2014). The SNAP 4Dx Plus test is currently only approved for use in dogs; however, this test has been successfully used to document antibodies to *A. phagocytophilum* and *Borrelia burgdorferi* in several other species, such as domestic cats, horses and sheep (only *A. phagocytophilum* antibodies have been studied in sheep using this test).

**Statistical analysis**

Power analysis was performed and revealed that 141 samples were needed to achieve a statistical power of 0.8, whereas 188 samples were required to reach a statistical power of 0.9. Data were analyzed using SAS statistical software and VassarStats online statistical software (http://vassarstats.net). The prevalence of *Anaplasma* species exposure (positive antibody response) and infection (presence of organism in blood sample on blood smear or via PCR) were determined for the study population. Fisher’s exact test was used to compare categorical variables between groups, ie, presence of anemia and *Anaplasma* species antibodies. A **χ**² test was used to compare the proportions of males and females testing positive for *Anaplasma* species exposure and acute infection. Data were considered statistically significant for *P* values ≤0.05.
Results

Blood samples were collected from 175 adult feral cats. Blood samples were inadequate to perform all laboratory tests for six cats, four of which only had a PCR analysis and SNAP 4Dx Plus test (IDEXX) performed. One cat had a CBC, blood smear evaluation and SNAP 4Dx Plus test performed but no PCR analysis. Another cat had a SNAP 4Dx Plus test performed but no CBC, blood smear evaluation or PCR analysis. Cats with missing data were excluded from analyses of variables for which there were missing data. There were 74 females and 84 males included in the study. There was no statistically significant difference between the proportions of males and females testing positive for anaplasmosis via PCR and/or positive antibody response (P = 0.888). Seventeen cats had no sex recorded at the time of sampling. The majority of cats were domestic shorthair cats (n = 117). Fifteen domestic longhair cats and seven domestic mediumhair cats were included, as well as one Siamese cat. The breed was not recorded at the time of sampling for 35 individuals.

Twelve cats tested PCR positive for *A phagocytophilum*, whereas 17 individuals were antibody positive for *A phagocytophilum* (Table 1). Seven of these cats were both PCR and antibody positive. Blood smear evaluation showed no evidence of *Anaplasma* species morulae within neutrophils in any sample. The prevalence of *Anaplasma* species exposure (antibody positive) was 9.7%, whereas the prevalence of acute infection, as indicated by a positive PCR assay, was 6.9%. CBC results are shown in Table 2. No correlations were found between cats being positive for *Anaplasma* species antibodies and the presence of anemia (P = 0.415) or thrombocytopenia (P >0.999). Similarly, no correlations were found between being PCR positive for *A phagocytophilum* and the presence of anemia (P = 0.524) or thrombocytopenia (P >0.999).

### Table 1

|                  | Positive samples | B burgdorferi co-exposure |
|------------------|------------------|---------------------------|
| Ap antibody (n = 175) | 17 (9.7)         | 4 (2.3)                   |
| Ap PCR (n = 173)   | 12 (6.9)         | 4 (2.3)                   |
| Ap PCR and antibody (n = 173) | 7 (4.0)         | 2 (1.2)                   |
| Bb antibody (n = 175) | 42 (24.0)      | –                         |

Data are n (%)

### Table 2

| CBC parameter (RI) | RI | Cats PCR positive for *A phagocytophilum* | Cats antibody positive for *A phagocytophilum* | Cats negative for *A phagocytophilum* antibodies and PCR | Total population |
|-------------------|----|----------------------------------------|---------------------------------------------|-------------------------------------------------|-----------------|
| Hematocrit (%)    | 28.2–52.7 | 31.9 (23.3–45.0) | 31.9 (23.5–45.0) | 31.1 (17.1–45.0) | 31.1 (17.1–45.0) |
| WBC count (K/μl)  | 3.9–19.0 | 7.608 (4.8–12.7) | 10.406 (4.90–19.70) | 7.829 (1.6–37.4) | 11.293 (1.6–37.4) |
| Neutrophil count (K/μl) | 2.620–15.170 | 4.614 (2.778–9.995) | 6.893 (2.014–15.682) | 7.892 (0.526–33.286) | 7.935 (0.526–33.286) |
| Lymphocyte count (K/μl) | 0.850–5.850 | 2.256 (1.215–4.284) | 2.565 (0.888–13.002) | 2.448 (0.449–17.280) | 2.562 (0.449–17.280) |
| Monocyte count (K/μl) | 0.040–0.530 | 0.179 (0–0.300) | 0.210 (0–0.394) | 0.269 (0–1.122) | 0.272 (0–1.122) |
| Eosinophil count (K/μl) | 0.090–2.180 | 0.551 (0.084–1.335) | 0.753 (0–2.243) | 0.640 (0–2.654) | 0.648 (0–2.654) |
| Platelet count (K/μl) | 155–641 | 400 (136–598) | 448 (221–807) | 448 (73–2677) | 459 (73–2677) |

Values for all parameters were found to be similar between groups, regardless of *Anaplasma phagocytophilum* infection or exposure status. No statistically significant correlations were identified for cats that were positive for *A phagocytophilum* on PCR analysis or SNAP 4Dx Plus, and the presence of anemia, thrombocytopenia, neutropenia or neutrophilia (P values ranged from 0.34–0.99 for these variables). Results expressed as mean (range) for each group.

RI = reference interval; WBC = white blood cell
B burgdorferi exposure was common with 24% of cats (42/175) testing positive for B burgdorferi antibodies (Table 1). Co-exposure was also identified with four individuals testing positive for B burgdorferi and A phagocytophilum antibodies. An additional four cats were positive on A phagocytophilum PCR analysis and tested positive for B burgdorferi antibodies. Two individuals tested positive on A phagocytophilum PCR analysis and tested positive for B burgdorferi and A phagocytophilum antibodies.

Discussion

The results of this study show that the prevalence of A phagocytophilum exposure and infection in feral cats in Massachusetts is higher than the previously published average seroprevalence of feline anaplasmosis in the USA.15 Massachusetts is an endemic area for both A phagocytophilum and its tick vector, I scapularis.1,12–14 Therefore, a higher prevalence would be expected in this area, which was confirmed by the results of the current study.

In this study, we included only feral cats in an effort to gauge the prevalence of A phagocytophilum infection and exposure in a population of cats that lived exclusively outdoors and were not treated with flea and tick preventatives. Our goal was to determine the true prevalence in free-ranging cats, in an effort to determine the risk for cats living in this region. Extrapolation of this information to cats that do not live exclusively outdoors and are treated with flea and tick preventatives may not be possible. However, the knowledge that the prevalence of A phagocytophilum infection and exposure in cats is higher than previously thought may help to guide diagnostic and therapeutic plans for cats in this area.

A recent study by Hoyt et al16 evaluated antibodies to A phagocytophilum and B burgdorferi in healthy and sick cats in Maine using a SNAP 4Dx Plus test (IDEXX).16 Nineteen percent of the cats in this study tested positive for antibodies to Anaplasma species.16 We now know that anaplasmosis can cause significant disease in cats and lead to lethargy, fever, decreased appetite, anemia, thrombocytopenia and polyarthropathy.4–11 The current study and the report from Maine show that there is a higher prevalence of anaplasmosis in cats in New England.16 This information should encourage clinicians in endemic areas to perform testing for Anaplasma species more readily in cats with clinical signs consistent with anaplasmosis. Furthermore, earlier detection of infection will allow for earlier treatment of these cats, which could improve clinical outcome.

The SNAP 4Dx Plus test (IDEXX) has been successfully used to document antibody response in cats experimentally infected, as well as those naturally infected with A phagocytophilum, though this test is not currently approved for use in this species.16–20 Further research into the use of the SNAP 4Dx Plus test is needed before this test can be recommended for routine use as a screening test in feline patients. Immunofluorescent antibody testing and PCR testing are currently available from commercial laboratories and are recommended for use at this time to document exposure and/or active infection in cats. Serologic testing is useful as a screening tool in asymptomatic patients to document exposure to the organism and may also be useful in patients with clinical disease. However, antibody testing may be negative early in the course of disease, prior to development of an antibody response. Also, a positive serologic test merely shows that the patient was exposed to the organism and does not prove current infection. PCR testing for A phagocytophilum is useful in patients with clinical illness and can be used as a confirmatory test for anaplasmosis. A limitation of PCR testing is that the test recognizes DNA and cannot confirm that the organism is living and causing disease. In addition, accuracy of PCR testing relies on strict laboratory protocols, as sample contamination can lead to false-positive results. Despite these limitations, PCR testing is the current recommended diagnostic to confirm anaplasmosis in feline patients.18,25,26 Alternatively, paired antibody titers showing a four-fold increase in titer performed 4 weeks after the initial titer may be used to confirm a diagnosis.4,9,10,18,25,26

Twenty-four percent (42/175) of the cats in this study had antibodies to B burgdorferi. Twenty-four percent (10/42) of these cats also tested positive for antibodies to A phagocytophilum and/or were PCR positive for A phagocytophilum. This highlights the fact that co-infections are common. Massachusetts and the New England region are highly endemic areas for A phagocytophilum and B burgdorferi, as well as their shared tick vector, I scapularis.12–14 As cats living in these endemic areas can harbor infection with both A phagocytophilum and B burgdorferi, they can act as silent hosts or carriers that allow these infections to persist in the environment. In addition, infected companion cats could harbor infected ticks and pose a risk to their human caretakers.

The Companion Animal Parasite Council reports prevalence information on A phagocytophilum infection in dogs in the USA.14 These data are listed by state, as well as by county. The prevalence of A phagocytophilum infection varies greatly from county to county in Massachusetts.14 We sought to compare the prevalence of feline anaplasmosis between counties in this study. The trappers confirmed that all cats participating in the study were trapped in the state of Massachusetts. However, we did not receive thorough information on the specific locations where the cats were trapped and were unable to report on this information. This would be an interesting area to investigate further in future studies.

We found no correlations between the presence of anemia or thrombocytopenia and being antibody or PCR positive for A phagocytophilum. This is in contrast to
previous reports of clinically ill cats exhibiting anemia and/or thrombocytopenia. However, the cats included in this study were apparently healthy and not showing signs of illness. We suspect that cats with clinical disease are more likely to exhibit these changes, whereas those with subclinical infections may not be afflicted with anemia and thrombocytopenia. Further research is needed to evaluate cats with clinical and subclinical infection to better characterize the clinicopathologic abnormalities.

This study has several limitations. First, no previous medical history was available for any of the cats in this study, as they were feral cats trapped for castration or ovariohysterectomy. Also, there was limited knowledge about the behavior and roaming patterns of these cats. Second, it is possible that some of the cats trapped could have been pets from the community and not truly feral or stray cats. Therefore, it is possible that they may have previously been treated with flea and tick preventatives and may have been housed indoors at some time in the past. If any of the cats in this study were previously treated with flea and tick preventatives and/or lived indoors, this would have decreased the likelihood of exposure to ticks and tick bites, which could have falsely decreased the prevalence of *A. phagocytophilum* infection and exposure in this study. Last, we were not able to get complete sample collections on all cats in this study, which was mostly likely due to peripheral vasoconstriction associated with the intramuscular sedation given prior to venipuncture. We were unable to perform all planned diagnostics on six cats in this study owing to short sampling or blood clots present in the sodium EDTA tubes.

**Conclusions**

This study shows that the prevalence of *A. phagocytophilum* infection and exposure in feral cats in Massachusetts are higher than the previously reported average seroprevalence of *A. phagocytophilum* in cats in the USA. Recent studies have shown that anaplasmosis can cause clinical disease in cats and *A. phagocytophilum* infection may be an emerging infectious disease in cats. Further research is needed to determine the prevalence of clinical illness associated with *A. phagocytophilum* infection in cats living in endemic areas.

**Acknowledgements**

We would like to thank Michael Thelen for his assistance with the statistical analysis for this study.

**Author note**

This article was presented, in part, in poster form at the ACVIM Forum in National Harbor, MD, USA, June 2017.

**Conflict of interest**

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Funding**

This study was supported by the Companion Animal Health Fund of Tufts University. Laboratory testing services for this study were provided by IDEXX Laboratories.

**References**

1. Severo MS, Stephens KD, Kotsyfakis M, et al. *Anaplasma phagocytophilum*: deceptively simple or simply deceptive? *Future Microbiol* 2012; 7: 719–731.
2. Mazepa AW, Kidd LB, Young KM, et al. Clinical presentation of 26 *Anaplasma phagocytophilum*-seropositive dogs residing in an endemic area. *J Am Anim Hosp Assoc* 2010; 46: 405–412.
3. Ravnik U, Tozon N, Smrdel KS, et al. Anaplasmosis in dogs: the relation of haematological, biochemical and clinical alterations to antibody titre and PCR confirmed infection. * Vet Microbiol* 2011; 149: 172–176.
4. Heikilä HM, Bondarenko A, Mihalkov A, et al. *Anaplasma phagocytophilum* infection in a domestic cat in Finland: case report. *Acta Vet Scand* 2010; 52: 62.
5. Schaarschmidt-Kiener D, Graf F, von Loewenich FD, et al. *Anaplasma phagocytophilum* infection in a cat in Switzerland. *Schweiz Arch Tierheilkd* 2009; 151: 336–341.
6. Tarello W. Microscopic and clinical evidence for *Anaplasma (Ehrlichia) phagocytophilum* infection in Italian cats. * Vet Rec* 2005; 156: 772–774.
7. Savidge C, Ewing P, Andrews J, et al. *Anaplasma phagocytophilum* infection of domestic cats: 16 cases from the northeastern USA. * J Feline Med Surg* 2016; 18: 85–91.
8. Adaszek Ł, Górna M, Skrzypczak M, et al. Three clinical cases of *Anaplasma phagocytophilum* infection in cats in Poland. *J Feline Med Surg* 2013; 15: 333–337.
9. Lappin MR, Breitschwerdt EB, Jensen WA, et al. Molecular and serologic evidence of *Anaplasma phagocytophilum* infection in cats in North America. * J Am Vet Med Assoc* 2004; 225: 893–896.
10. Bjöersdorff A, Svendenius L, Owens JH, et al. Feline granulocytic ehrlichiosis – a report of a new clinical entity and characterisation of the infectious agent. *Small Anim Pract* 1999; 40: 20–24.
11. Lappin MR, Griffin B, Brunt J, et al. Prevalence of *Bartonella* species, *Haemoplasma* species, *Ehrlichia* species, *Anaplasma phagocytophilum*, and *Neorickettsia risticii* DNA in the blood of cats and their fleas in the United States. * J Feline Med Surg* 2006; 8: 85–90.
12. Centers for Disease Control and Prevention. Annual cases of anaplasmosis in the United States. [https://www.cdc.gov/anaplasmosis/stats/](https://www.cdc.gov/anaplasmosis/stats/) (2016, accessed March 17, 2016).
13. Little SE, Beall MJ, Bowman DD, et al. Canine infection with *Dirofilaria immitis*, *Borrelia burgdorferi*, *Anaplasma spp.*, and *Ehrlichia* spp. in the United States, 2010–2012. *Parasit Vectors* 2014; 7: 257.
14. Companion Animal Parasite Council. CAPC parasite prevalence maps – anaplasmosis state of Massachusetts 2015. [https://www.capcvet.org/parasite-prevalence-maps/](https://www.capcvet.org/parasite-prevalence-maps/) (2015, accessed March 15, 2017).
15. Billetter SA, Spencer JA, Griffin B, et al. Prevalence of *Anaplasma phagocytophilum* in domestic felines in the United States. * Vet Parasitol* 2007; 147: 194–198.
16. Hoyt K, Chandrashekar R, Breitschwerdt E, et al. *Anaplasma phagocytophilum* and *Borrelia burgdorferi*
antibodies in naturally exposed cats in Maine. ACVIM Forum Research Abstracts Program. J Vet Intern Med 2014; 28: 1068.

17 Saucier J, Leonard B, Hoyt K, et al. Seroprevalence of antibodies to *Anaplasma phagocytophilum* and *Borrelia burgdorferi* in domestic cats. ACVIM Forum Research Abstracts Program. J Vet Intern Med 2016; 31: 1479.

18 Lappin MR, Chandrashekar R, Stillman B, et al. Evidence of *Anaplasma phagocytophilum* and *Borrelia burgdorferi* infection in cats after exposure to wild-caught adult *Ixodes scapularis*. J Vet Diagn Invest 2015; 27: 522–525.

19 Hegarty BC, Qurollo BA, Thomas B, et al. Serological and molecular analysis of feline vector-borne anaplasmosis and ehrlichiosis using species-specific peptides and PCR. Parasit Vectors 2015; 8: 320.

20 Ravicini S, Pastor J, Hawley J, et al. Prevalence of selected infectious disease agents in stray cats in Catalonia, Spain. JFMS Open Rep 2016; 2: DOI: 10.1177/2055116916634109.

21 Hansen MG, Christoffersen M, Thuesen LR, et al. Seroprevalence of *Borrelia burgdorferi* sensu lato and *Anaplasma phagocytophilum* in Danish horses. Acta Vet Scand 2010; 52: 3.

22 Veronesi F, Passamonti F, Moretti A, et al. Evaluation of the performance of a rapid enzyme-linked immunosorbent assay in the detection of *Anaplasma phagocytophilum* antibodies in horses. Vector Borne Zoonotic Dis 2014; 14: 317–323.

23 Chandrashekar R, Daniluk D, Moffitt S, et al. Serologic diagnosis of equine borreliosis: evaluation of an in-clinic enzyme-linked immunosorbent assay (SNAP 4Dx). Int J Appl Res Vet Med 2008; 6: 145–150.

24 Granquist EG, Stuen S, Crosby L, et al. Variant-specific and diminishing immune responses towards the highly variable MSP2(P44) outer membrane protein of *Anaplasma phagocytophilum* during persistent infection in lambs. Vet Immunol Immunopathol 2010; 133: 117–124.

25 Bergmann M and Hartmann K. Vector-borne diseases in cats in Germany. Tierarztl Prax Ausg K Kleintiere Heimtiere 2017; 45: 329–335.

26 Pennisi MG, Hofmann-Lehmann R, Radford AD, et al. *Anaplasma, Ehrlichia* and *Rickettsia* species infections in cats: European guidelines from the ABCD on prevention and management. J Feline Med Surg 2017; 19: 542–548.